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Sunmary Bolus infusional 5-fluorouracil (5-FU) and folinic acid (FA) is reported to be highly active [partial
response (PR) = 54%, median survival 18 months] in patients with metastatic colorectal carcinoma (MCCa).
To confirm this level of activity, we conducted a retrospective analysis of 95 previously untreated patients with
MCCa treated with FA by 2 h i.v. infusion (200 mg m-) followed by 5-FU bolus/22 h i.v. infusion
(300-500mg m-) on days 1 and 2 every 2 weeks. Thirty patients also received N-phosphonacetyl)-L-
aspartate (PALA). 250 mg m- 24 h prior to 5-FU FA. In 81 evaluable patients, the response rate was low:
PR = 11%, stable disease (SD) = 36% and median survival = 8 months. There was an improvement in
survival with incresed 5-FU dosage (500 mg m-) [relative hazard (RH) = 0.38, 95% CI 0.21-0.70], controlled
for age, primary site, PALA, liver function and performance status. Good performance status (PS 0 or 1) was
also associated with improved survival (RH = 0.21, 95% CI 0.10-0.46). Response, survival and toxicity were
not altered by the co-administration of PALA. Bolus/infusional 5-FU (500 mg m-2) and FA was well
tolerated. WHO toxicities (grade 3) were: mucositis, 2%; diarrhoea, 14%; nausea and vomiting, 5%. In light
of the apparent dose effect. poor response and low toxicity, we recommend that regimes incorporating higher
5-FU dosages are explored and prospectively validated before bolus infusional 5-FU becomes accepted
standard practice.
The fluorinated pynrmidine 5-fluorouracil (5-FU) is the most
extensively used drug in metastatic colorectal cancer,
although a meta-analysis (Advanced Colorectal Cancer
Meta-Analysis Project, 1992) has shown that the response
rate achieved using conventional bolus administration
schedules is only 11%. Because of this low response rate,
interest has focused on the modulation of 5-FU activity. A
major locus of action of 5-FU is the enzyme thymidylate
synthase (TS), the enzyme responsible for the formation of
dTMP from dUMP. The 5-FU metabolite FdUMP is a
potent inhibitor of TS (Cohen et al., 1958), forming an
irreversible ternary complex with TS and the co-factor 5,10-
CH,-tetrahydrofolate (5,10-CH,-FH4). Reduced intracellular
concentrations of 5,10-CH,-FH4 may therefore limit the for-
mation of the ternary complex and hence limit the cytotox-
icity of 5-FU. This hypothesis provides the rationale for the
use of 5-FU in combination with folinic acid (5-CHO-FH4),
which is readily converted to 5,10-CH2-FH4, increasing the
formation of ternary complex. A number of clinical studies
have shown that the combination of 5-FU with folinic acid
enhances the activity of 5-FU in patients with metastatic
colorectal cancer (Grem et al., 1987).
Although the addition of folinic acid to 5-FU has been
shown to improve response rates, this may occur at the
expense of increased toxicity. In the initial reports of a widely
used 5-FU/folinic acid combination administered to out-
patients at weekly intervals [2 h infusion of folinic acid
(500 mgm-2) with a bolus dose of 5-FU (600 mgm-2)
administered 1 h into the folinic acid infusion] a high
incidence (40%) of dose-limiting diarrhoea was observed
(Petrelli et al., 1987).
An alternative approach to the combination of 5-FU and
folinic acid has been developed (De Gramont et al., 1988). In
this regimen a 2 h infusion of folinic acid (200 mg m-) is
followed by both a bolus (300-500 mgm-2) and 22 h
infusion (300-500 mg m-2) of 5-FU. This schedule is
repeated on day 2 and repeated at 2 weekly intervals.
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Preliminary results demonstrated good activity (response
rate = 54% CI 38-70%) and the regimen was well tolerated.
In the initial 37 patients reported no WHO grade 3 toxicities
were noted. A second study confirmed that the regimen is
well tolerated, although response rates were lower: overall
response=24% (95% CI 11-37%) (Johnson et al., 1991);
overall response = 30% (n = 82) (Seymour et al.. 1994).
Because it is well tolerated and apparently active, the 'De
Gramont' regimen is used frequently as initial therapy for
metastatic colorectal cancer within the UK. However, in
Glasgow the regimen has required 48 h in-patient admission
in addition to the financial cost of folinic acid and therefore
we considered it necessary to confirm the activity of the
regimen before adopting it as standard practice. Therefore,
we performed a retrospective analysis of all patients receiving
bolus/infusional 5-FU/folinic acid for metastatic colorectal
cancer at the Beatson Oncology Centre between March 1991
and May 1992.
Patients and methods
All patients had histologically proven colorectal cancer and
clinical evidence of metastatic or locally recurrent disease.
Patients were excluded from analysis if they had received
previous 5-FU chemotherapy. Standard WHO criteria for
assessability were applied, and measurable disease was
generally assessed by clinical examination. X-ray, ultrasono-
graphy or CT scanning. Prior to commencing chemotherapy
all patients underwent a complete physical examination and a
full blood count and plasma biochemical profile were
obtained.
The treatment regimen is shown in Table I. Thirty patients
(31% of patients) also received an infusion of 250mgm-'
N-(phosphonacetyl)-L-aspartic acid (PALA) 24h prior to
commencing bolus/infusional 5-FU/folinic acid. PALA is an
inhibitor of the enzyme L-aspartic acid transcarbamoylase
(ATCase), which is important in de novo pyrimidine synthesis
and has been shown to modulate 5-FU activity (Martin et
al.. 1983). PALA was administered in an out-patient clinic on
the day prior to a 48 h admission for 5-EU folinic acid.
Treatment was repeated at 2 weekly intervals provided that
non-haematological toxicities (mucositis and diarrhoea) had
resolved and that WBC was > 3.0 x I091' and platelets
> 100 x I091-'. 5-FU was administered at three dose levels
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Table I Drug regimen used in this study - repeated every 2
weeks
Dosage Timne Infusion duration
Drug (mg m- 2) (h) (h)
PALAa 250 -24 15-20 min
Folinic acid 200 0 2 h
5-FU 300-500 2 10 min (bolus)
5-FU 300-500 2.17 22 h
Folinic acid 200 24 2 h
5-FU 300-500 26 10min (bolus)
5-FU 300-500 26.17 22 h
"In 30 patients.
(bolus and infusion): 300 mg m-2, three patients; 400 mg
m 2, 47 patients; 500 mg m2', 45 patients. The results for the
300 and 400 mg m-' dose levels were combined.
Details of sex, age, primary site (colon/rectum), pretreat-
ment performance status and function were also extracted
from case notes. Toxicity associated with previous cycles of
chemotherapy was recorded at each visit using WHO toxicity
criteria.
Statistical methods
Survival analyses with covariates were performed using the
computer programs BMDP 1L and 2L. Covariates included
were: age, co-administration of PALA, 5-FU dosage, perfor-
mance status (WHO grade), primary site (colon or rectum)
and biochemical tests of liver function (ALP, AST and
bilirubin). Survival curves were generated using the Kap-
lan-Meier method (Kaplan & Meier, 1958). Chi-squared
tests of association and trend were used as appropriate.
Results
Patients
Ninety-five patients (no previous chemotherapy) received the
bolus/infusional 5-FU,folinic acid regimen between March
1991 and May 1992. The median age was 60 (range 27-83)
and 55 were male (40 female). Peformance status was
generally good: PS 0, 23; PS 1, 55; PS 2, 10; PS 3, 3; PS not
recorded 4. In 58 patients the primary disease site was the
colon (37 rectum). In 81 patients (85%) sufficient information
was available to make them assessable for response. Reasons
for inevaluability (n = 14) were as follows: seven patients, no
measurable disease; two patients, previous radiotherapy to
marker lesion; one patient, toxic death; one patient myocar-
dial infarct after one cycle; one patient, refused further treat-
ment after three cycles and was not reassessed; one patient.
died after three cycles and details of cause of death were not
available; one patient, developed cerebral metastases after
four cycles and systemic disease was not reassessed.
Responsefollowing chemotherapy-
The overall response rate (Table II) was low when assessed 2
months (four cycles) after starting treatment, with only 9 out
of 81 evaluable patients (I11%. 95% CI = 4-18%) achieving
an objective partial response. Disease remained stable in a
further 29 patients (36%). The response rates for the different
5-FU dosage regimens and pretreatment performance status
are also shown in Table II. Although it was observed that a
lower proportion of patients treated at the highest 5-FU
dosage (500 mgm-2) progressed on treatment, this difference
is not statistically significant (yjd = 0.51, 1 d.f., P = 0.48).
Pretreatment performance status had a statistically significant
effect on response. If PR + SD and WHO performance status
grades 2 and 3 are combined, then patients with a better
performance status are more likely to respond (/,r= 5.78,
1 d.f.. P = 0.02). There was no evidence that co-
administration of PALA, the presence of visceral metastases.
the site of the primary tumour or abnormal liver function
tests (ALP. AST, bilirubin) was associated with a change in
response rates (data not shown).
Survivalfollow ing chemotherapy
The median survival was 8 months. Seventy-six patients had
died, and the median follow-up time in survivors was 17
months (range 9-27). There was a difference in survival
between the two 5-FU dosage groups ([log-rank Z' = 4.87, 1
d.f.. P = 0.03; relative hazard (95% CI) = 0.61 (0.38-0.97]).
Adjusting simultaneously for the effects of performance
status. age, PALA. liver function (ALP, AST. bilirubin),
using a Cox proportional hazards regression model. the effect
of 5-FU dosage was even more marked ([relative hazard
(95% CI)= 0.38 (0.21-0.70); Z'= 10.18. 1 d.f., P=0.001])
(see Figure 1). Using a stepwise selection procedure, it was
found that 5-FU dosage, performance status, bilirubin and
the site of primary disease are independently related to sur-
vival. The relative hazards (95% CI) are: 500 mg m-7 5-FU
dosage, 0.43 (0.26-0.73); performance status 0 or 1. 0.21
(0.10-0.46); bilirubin normal, 0.18 (0.06-0.51); and primary
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Figre I An improvement in median survival was associated
with the higher 5-FU dosage: 300-400mgm-I (...). 5 months;
500 mg m-2 (-). 9 months. Relative hazard = 0.38. 95°<O
CI = 0.21-0.70. adjusting simultaneously for the effects of PS.
age. PALA. primary site and liver function.
Table II Response data
Partial response (PR) Stable disease (SD) PR + SD Progression (PD)
Overall (n= 81) 9 (11%) 29 (36%) 38 (47%) 43 (53%)
5-FU dosage (mgmr-2)
500 5 (12%) 16 (39%) 21 (51%) 20 (49%)
300-400 4 (10%) 13 (32%) 17 (42%) 23 (58%)
Performance status
0 3 (14%) 10 (48%) 13 (62%) 8 (38%)
1 5 (11%) 17 (37%) 22 (48%) 24 (52%)
2+3 1 (8%) 1 (8%) 2 (17%) 10 (83%)5-FU FOLINIC ACID CHEMOTHERAPY FOR COLORECTAL CANCER 751
Using a Cox proportional hazard model, the effect of
symptoms (PS 1) vs no symptoms (PS 0) was not significant
(relative hazard = 1.17. 95% CI 0.61-2.24, y=0.24, I d.f.,
P = 0.62) in a survival analysis adjusting simultaneously for
age. 5-FU dosage, primary site, PALA and liver function
(ALP, AST, bilirubin) (Figure 2).
Toxicity associated with chemotherapy
The regimen was generally well tolerated even at the higher
5-FU dosage (500 mg m-). One patient developed grade 3
diarrhoea in association with grade 4 leucopenia and died.
This was considered to be a toxic death. Dosage was reduced
as result of diarrhoea in seven patients (5;500-400 mg m2,
2; 400-300 mg m2) and mucositis in one patient
(500-400 mg m2. In total, leucopenia was seen in three
patients (two grade 4, one grade 2) and 5-FU dosage was
reduced (500-400mgm-2) in one patient. Hand-foot syn-
drome led to dosage reduction in 1 patient (400-300 mg
m2). Superficial thrombophlebitis was also noted in a
number of patients and rhinitis with blood-stained mucus
was described.
There did appear to be an increase in toxicity with the
increased 5-FU dosage (Table III). However, these increases
were not statistically significant individually. Mucositis
(WHO grade 2,3) was seen in seven patients (16%) at
500 mg m- 5-FU compared with two patients (4%) at
300-400mgm-'; = 1.32, 1 d.f., P=0.25. A similar
pattern was seen with diarrhoea (It = 2.76, 1 d.f., P = 0.1)
and nausea and vomiting (Ij = 0.57, 1 d.f.. P = 0.45). To
give a single overall measure, toxicity was summed (mucositis
WHO grade + diarrhoea WHO grade + nausea/vomiting
WHO grade) for individual patients. Grouping 0 and 1
(minimal overall toxicity), 2 and 3 (moderate) and >r 4
(severe), there was a significant increase (X2f, = 4.44, 1 d.f..
P = 0.04) in overall toxicity associated with the higher 5-FU
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Figure 2 In a survival analysis (P2L) adjusting simultaneously
for age, 5-FU dosage, primary site, PALA and liver function
(ALP, AST, bilirubin) using a Cox proportional hazard model.
the effect of symptoms (PS 1) vs asymptomatic status (PS 0) was
not significant (relative hazard= 1.17. 95% CI 0.61-2.24).
There was no evidence that other variables including per-
formance status and PALA co-administration significantly
altered the incidence of toxicity.
This paper has described a restrospective analysis of 95
patients with metastatic colorectal cancer treated using the
5-FU/folinic acid regimen described by De Gramont et al.
(1988). In agreement with other authors (Johnson et al..
1991; Seymour et al., 1994) we found the regimen to be well
tolerated with a low incidence of WHO grade ) 3 toxicity.
However, although well tolerated, evidence of anti-tumour
activity using this regimen was disappointing and did not
approach the response rate (54%) or median survival (18
months) which had previously been reported (De Gramont et
al., 1988). It is accepted that response rates may vary
between studies as a result of interpretation of response
criteria and the difficulty in obtaining reproducible bi-
dimensional measurements using present imaging techniques.
However, in this study in responding patients response dura-
tion was short (median 4 months) and median survival was
also shorter (8 months) than that previously reported for this
regimen.
The multivariate analysis reported in this paper was per-
formed in an attempt to identify factors which may have
been responsible for our poor results. All patients included in
the analysis had received no prior chemotherapy. The ages of
patients studied (median 60. range 27-83) are similar to
those in the original report (median 62, range 38-79), and in
the multivariate analysis age did not affect survival. Perfor-
mance status is well recognised as a predictor of outcome in
chemotherapy trials. In this analysis the number of patients
treated with performance status > I was small (13). However
performance status (0,1 vs 2,3) did have a significant effect on
survival and also on response if PR and SD are combined
(Table III). In patients with PS = O (i.e. asymptomatic) the
response rate was 14% (3/21 evaluable) and median survival
was 10 months. Therefore PS does not appear to explain the
discrepancy between our results and those of De Gramont et
al. (1988). It was also noted that there was no survival
difference in patients who were asymptomatic (PS 0) and
those who were symptomatic (PS = 1) (Figure 2).
Three different dosages of 5-FU were administered to
patients, although the folinic acid dosage (200 mg m2 ) and
infusion schedule (Table I) remained constant. Therefore, as
part of the multivariate analysis, 5-FU dosage was assessed
as an independent predictor of response and survival and a
trend towards improved survival with increased 5-FU dosage
was demonstrated (Figure 1). However, the response rate and
survival at the higher 5-FU dosage remains disappointing:
(5 41 evaluable = 12%, 95% CI = 2-22%, median sur-
vival =9 months).
The most common grade 3 toxicity was diarrhoea, and yet
this occurred in only 6/43 (14%) patients treated at a 5-FU
dosage of 500 mg m-2. In one patient severe toxicity includ-
ing grade 4 neutropenia was encountered, and this patient
probably died as a result of drug-induced toxicity. Sporadic
severe toxicity has been previously reported in patients
receiving 5-FU, and this phenomenon has been associated
with evidence of reduced activity of the enzyme dihydro-
pyrimidine dehydrogenase (DPD) (Lilenbaum et al.. 1991).
Table III Toxicity graded using WHO criteria and split by 5-FU dosage (mgm-2). Numbers represent worst toxicity at anv
course
Afucositis Diarrhoea Nausea and vomiting 400Xmgm-2 5-FL 500mgm- ' 5-FU' 400(mgm' 5-FL 500 mgm-- 5-FU 400mgmr- 5-FU 500 mgm-2 5-FU WHO grade (n =46) (n =43) (n = 46)a (n =43) (n =46) (n =43)
0 33 (72%) 29 (67%) 30 (65%) 22 (51%) 21 (46%) 17 (40%) 1 11(24%) 7 (16%) 9 (20%) 8 (19%) 18 (39%) 17 (400/6) 2 2 (4%) 6 (14%) 6 (13%) 7 (16%) 6 (13%) 7 (16°o) 3 0 1 (2%) 1 (2%) 6 (14%) 1 (2%) 2 (50'.)
"Includes three patients who received 5-FU; 300 mgm-.752 D.I. JODRELL et al.
but clinical material which might allow the diagnosis of such
an enzyme deficiency was not available.
Two toxicities were encountered which had not been
anticipated prior to the study. A number of patients noted a
superficial phlebitis associated with peripheral infusion sites,
and these were occasionally ulcerating. However, phlebitis
did not lead to treatment being discontinued in any patients.
A number of patients also complained of blood-stained nasal
discharge. This was not associated with thrombocytopenia or
any other clotting disorder and was thought to be associated
with a nasal mucositis similar to that noted in the gastro-
intestinal tract.
The low incidence of toxicity seen in our analysis and the
improved survival with higher 5-FU dosage suggests that
higher 5-FU dosage or 5-FU dose intensity may lead to
improved anti-tumour activity. The dose intensity of the
5-FU/fohnic acid regimen used in the study reported here is
5-FU 1,000 mg m week ' and folinic acid 200 mg m
week-'. In comparison, a regimen has been reported in
which the 5-FU dose intensity (in combination with folinic
acid) has been escalated to 2,600 mg m-' week-' and folinic
acid dose intensity to 500 mg m2 week-' (Ardalan et al..
1992). In this study high response rates, albeit in small
numbers of patients, have been reported.
We feel that the response rate and survival duration of the
order seen in our analysis do not justify the cost of admini-
stration in terms of both drug costs and, in our experience in
Glasgow. in-patient care. Patients were admitted fbr two
nights every 2 weeks and this is likely to have a negative
impact upon quality of life. In one patient this was stated as
the cause of significant psychological morbidity and
premature cessation of therapy. However, we are sensitive to
the fact that this paper describes a retrospective analysis and
are aware of the importance of performing carefully
monitored prospective analyses of drug regimens. For this
reason we are now accruing patients into a formal prospec-
tive analysis of this regimen at the higher 5-FU dosage
(500 mg m -). In order to limit the number of patients
treated using a potentially suboptimal regimen we have
initiated a prospective phase II study using a sequential
triangular procedure (Whitehead, 1983) for response analysis.
On completion of this study we propose to explore the
potential for dose,dose intensity escalation which we feel
exists. In the meantime we caution against the use of the
5-FU/folinic acid regimen described in this paper as 'uncon-
trolled standard therapy'.
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